rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

Phase 3

Terminated

• Conditions: Paroxysmal Nocturnal Hemoglobinuria
• Interventions: Drug: rVA576 (Coversin)

• Registration Number: NCT03829449
• Lead Sponsor: AKARI Therapeutics

Brief Summary

Patients with diseases requiring complement inhibition who have previously taken part in Akari clinical trials and who wish to continue to receive rVA576 (Coversin) after their active participation in the parent trial has completed and patients treated under compassionate use or named patient arrangements who wish to continue on rVA576 (Coversin) therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-13
• Study First Submitted: 2018-12-20
• Study First Submitted QC: 2019-02-01
• Study First Posted: 2019-02-04
• Primary Completion: 2020-08-29
• Study Completion: 2020-08-29
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-22
• Last Update Posted: 2021-06-28

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Patients 18 years and above treated with rVA576 (Coversin) under other Akari clinical trial protocols and wish to remain on rVA576 (Coversin) at the conclusion of that trial.
2. In the opinion of the treating responsible clinician patient is receiving clinical benefit from continued treatment with study drug.
3. Evidence of sustained complement inhibition by CH50 assay. .
4. Women of childbearing potential (WOCBP) must agree to use effective contraception consistently throughout the study and have a negative pregnancy test at screening and a negative urine pregnancy test per the schedule of visits. Women cannot donate their eggs. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of amenorrhea or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks previously.
5. Males with a childbearing potential partner must agree to use effective contraception consistently OR have had a vasectomy
6. Weight ≥50-100kg
7. Willing to receive appropriate prophylaxis against Neisseria meningitidis infection, by both immunisation and continuous or intermittent antibiotics
8. The patient is willing to give voluntary written informed consent
9. The patient is willing in the process of preparation and self-administration of the study drug.

Read More

Exclusion Criteria

1. Patient experienced any safety event in the previous study protocol, which puts the patient at unacceptable risk in current protocol as judged by the investigator and sponsor.
2. Patient is unwilling to complete the Quality of Life instruments and diary card
3. Active meningococcal infection (section 4.3.1 for additional information)
4. Any other reason for which, in the opinion of the Investigator, it would not be in the interests of the patient to remain on rVA576 (Coversin).
5. If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 90 days after last dose; or intending to donate ova during such time period.
6. If male, the subject intends to donate sperm while on the study this study or for 90 days after last dose.
7. Failure to satisfy the Investigator of fitness to participate for any other reason or any other condition which, in the opinion of the investigator, could increase the subject's risk by participating in the study or confound the outcome of the study.
8. Use of prohibited medication
9. The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse.
10. Participation in other clinical trials with investigational product.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
rVA576 Coversin	rVA576 (Coversin)	The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.

Primary Outcome Measures

Name	Time	Method
Long term safety and efficacy of rVA576 (Coversin) therapy assessed by AEs, SAEs, Standard Lab tests and ECG results.	4 years	To determine the safety profile of long-term rVA576 (Coversin) treatment as assessed by AEs, SAEs, Standard Lab tests and ECG results.

Secondary Outcome Measures

Name	Time	Method
Proportion of subjects who require PRBC transfusion during each 3-month period since the start of the study and over the entire period of the study	4 years	Proportion of subjects who require PRBC transfusion during each 3-month period since the start of the study and over the entire period of the study
Number of Major Adverse Vascular Events (MAVE) over the entire period of the study.	4 years	Number of Major Adverse Vascular Events (MAVE) over the entire period of the study.
Time to first transfusion since joining the study.	4 years	Time to first transfusion since joining the study.
Proportion of transfusion-independent subjects at each 3-month time point, with haemoglobin (g/L) above the baseline haemoglobin value they had at the start of the trial from which they entered CONSERVE	3 monthly	Proportion of transfusion-independent subjects at each 3-month time point, with haemoglobin (g/L) above the baseline haemoglobin value they had at the start of the trial from which they entered CONSERVE
Proportion of subjects with thrombotic and haemolytic event free status during each 3month time period since the start of the study.	12 weeks	Proportion of subjects with thrombotic and haemolytic event free status during each 3month time period since the start of the study.
Time to thrombotic or haemolytic event since joining this study.	4 years	Time to thrombotic or haemolytic event since joining this study.
Proportion of subjects with no adverse change in overall scores of Quality of Life using the EORTC QLQ-C30, the EQ-5D-5L and FACIT-F instruments at each 3-month time period since the start of the study.	12 weeks	Proportion of subjects with no adverse change in overall scores of Quality of Life using the EORTC QLQ-C30, the EQ-5D-5L and FACIT-F instruments at each 3-month time period since the start of the study.
Proportion of subjects with serum Lactate Dehydrogenase (LDH) <1.8, >1.8 to 2.4, >2.4 to 3, and >3 times the upper limit of normal (ULN) at each 3-month time period since the start of the study.	12 weeks	Proportion of subjects with serum Lactate Dehydrogenase (LDH) \<1.8, \>1.8 to 2.4, \>2.4 to 3, and \>3 times the upper limit of normal (ULN) at each 3-month time period since the start of the study.
Time to first Major Adverse Vascular Event (MAVE) for each subject since joining the study.	4 years	Time to first Major Adverse Vascular Event (MAVE) for each subject since joining the study.
Proportion of subjects with median serum Lactate Dehydrogenase (LDH) <1.8, >1.8 to 2.4, >2.4 to 3, and >3 times the upper limit of normal (ULN) over the entire duration of the study.	4 years	Proportion of subjects with median serum Lactate Dehydrogenase (LDH) \<1.8, \>1.8 to 2.4, \>2.4 to 3, and \>3 times the upper limit of normal (ULN) over the entire duration of the study.
Proportion of transfusion-independent subjects over the entire duration of the study with mean haemoglobin (g/L) above the baseline haemoglobin value they had at the start of the trial from which they entered CONSERVE	12 weeks	Proportion of transfusion-independent subjects over the entire duration of the study with mean haemoglobin (g/L) above the baseline haemoglobin value they had at the start of the trial from which they entered CONSERVE
Proportion of patients experiencing Major Adverse Vascular Events (MAVE) over the entire period of the study.	4 years	Proportion of patients experiencing Major Adverse Vascular Events (MAVE) over the entire period of the study.

Trial Locations

Locations (1)

Instytut Hematologii i Transfuzjologii; 🇵🇱 Warsaw, Poland